Search

Your search keyword '"Crichton, Megan"' showing total 338 results
Start Over Author "Crichton, Megan"
338 results on '"Crichton, Megan"'

2. Bronchiectasis and asthma: Data from the European Bronchiectasis Registry (EMBARC)

Author

Polverino, Eva, Dimakou, Katerina, Traversi, Letizia, Bossios, Apostolos, Haworth, Charles S., Loebinger, Michael R., De Soyza, Anthony, Vendrell, Montserrat, Burgel, Pierre-Régis, Mertsch, Pontus, McDonnell, Melissa, Škrgat, Sabina, Maiz Carro, Luis, Sibila, Oriol, van der Eerden, Menno, Kauppi, Paula, Hill, Adam T., Wilson, Robert, Milenkovic, Branislava, Menendez, Rosario, Murris, Marlene, Digalaki, Tonia, Crichton, Megan L., Borecki, Sermin, Obradovic, Dusanka, Nowinski, Adam, Amorim, Adelina, Torres, Antoni, Lorent, Natalie, Welte, Tobias, Blasi, Francesco, Van Braeckel, Eva, Altenburg, Josje, Shoemark, Amelia, Shteinberg, Michal, Boersma, Wim, Elborn, J. Stuart, Aliberti, Stefano, Ringshausen, Felix C., Chalmers, James D., and Goeminne, Pieter C.

Published
2024
Full Text
View/download PDF

7. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)

Author

Chalmers, James D, Polverino, Eva, Crichton, Megan L, Ringshausen, Felix C, De Soyza, Anthony, Vendrell, Montserrat, Burgel, Pierre Régis, Haworth, Charles S, Loebinger, Michael R, Dimakou, Katerina, Murris, Marlene, Wilson, Robert, Hill, Adam T, Menendez, Rosario, Torres, Antoni, Welte, Tobias, Blasi, Francesco, Altenburg, Josje, Shteinberg, Michal, Boersma, Wim, Elborn, J Stuart, Goeminne, Pieter C, and Aliberti, Stefano

Published
2023
Full Text
View/download PDF

14. Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations

Author

Aliberti, Stefano, Goeminne, Pieter C, O'Donnell, Anne E, Aksamit, Timothy R, Al-Jahdali, Hamdan, Barker, Alan F, Blasi, Francesco, Boersma, Wim G, Crichton, Megan L, De Soyza, Anthony, Dimakou, Katerina E, Elborn, Stuart J, Feldman, Charles, Tiddens, Harm, Haworth, Charles S, Hill, Adam T, Loebinger, Michael R, Martinez-Garcia, Miguel Angel, Meerburg, Jennifer J, Menendez, Rosario, Morgan, Lucy C, Murris, Marlene S, Polverino, Eva, Ringshausen, Felix C, Shteinberg, Michal, Sverzellati, Nicola, Tino, Gregory, Torres, Antoni, Vandendriessche, Thomas, Vendrell, Montserrat, Welte, Tobias, Wilson, Robert, Wong, Conroy A, and Chalmers, James D

Published
2022
Full Text
View/download PDF

16. Essential elements of optimal dietary and exercise referral practices for cancer survivors: expert consensus for medical and nursing health professionals

Author

Joseph, Ria, Hart, Nicolas H., Bradford, Natalie, Wallen, Matthew P., Han, Chad Y., Pinkham, Elizabeth P., Hanley, Brigid, Lock, Gemma, Wyld, David, Wishart, Laurelie, Koczwara, Bogda, Chan, Alexandre, Agbejule, Oluwaseyifunmi Andi, Crichton, Megan, Teleni, Laisa, Holland, Justin J., Edmiston, Kelli, Naumann, Leonie, Brown, Teresa, and Chan, Raymond J.

Published
2023
Full Text
View/download PDF

18. Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study

Author

Keir, Holly R, Shoemark, Amelia, Dicker, Alison J, Perea, Lidia, Pollock, Jennifer, Giam, Yan Hui, Suarez-Cuartin, Guillermo, Crichton, Megan L, Lonergan, Mike, Oriano, Martina, Cant, Erin, Einarsson, Gisli G, Furrie, Elizabeth, Elborn, J Stuart, Fong, Christopher J, Finch, Simon, Rogers, Geraint B, Blasi, Francesco, Sibila, Oriol, Aliberti, Stefano, Simpson, Jodie L, Huang, Jeffrey T J, and Chalmers, James D

Published
2021
Full Text
View/download PDF

20. Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)

Author

Spinou, Arietta, primary, Hererro-Cortina, Beatriz, additional, Aliberti, Stefano, additional, Goeminne, Pieter C, additional, Polverino, Eva, additional, Dimakou, Katerina, additional, Haworth, Charles S, additional, Loebinger, Michael R, additional, De Soyza, Anthony, additional, Vendrell, Montserrat, additional, Burgel, Pierre Regis, additional, McDonnell, Melissa, additional, Sutharsan, Sivagurunathan, additional, Skrgat, Sabina, additional, Maiz-Carro, Luiz, additional, Sibila, Oriol, additional, Stolz, Daiana, additional, Kauppi, Paula, additional, Bossios, Apostolos, additional, Hill, Adam T, additional, Clifton, Ian, additional, Crichton, Megan L, additional, Walker, Paul, additional, Menendez, Rosario, additional, Borecki, Sermin, additional, Obradovic, Dusanka, additional, Nowinski, Adam, additional, Amorim, Adelina, additional, Torres, Antoni, additional, Lorent, Natalie, additional, Welte, Tobias, additional, Blasi, Francesco, additional, Makek, Mateja Jankovic, additional, Shteinberg, Michal, additional, Boersma, Wim, additional, Elborn, J Stuart, additional, Chalmers, James D, additional, and Ringshausen, Felix C, additional

Published
2024
Full Text
View/download PDF

23. Bronchiectasis and asthma:Data from the European Bronchiectasis Registry (EMBARC)

Author

Polverino, Eva, Dimakou, Katerina, Traversi, Letizia, Bossios, Apostolos, Haworth, Charles S., Loebinger, Michael R., De Soyza, Anthony, Vendrell, Montserrat, Burgel, Pierre Régis, Mertsch, Pontus, McDonnell, Melissa, Škrgat, Sabina, Maiz Carro, Luis, Sibila, Oriol, van der Eerden, Menno, Kauppi, Paula, Hill, Adam T., Wilson, Robert, Milenkovic, Branislava, Menendez, Rosario, Murris, Marlene, Digalaki, Tonia, Crichton, Megan L., Borecki, Sermin, Obradovic, Dusanka, Nowinski, Adam, Amorim, Adelina, Torres, Antoni, Lorent, Natalie, Welte, Tobias, Blasi, Francesco, Van Braeckel, Eva, Altenburg, Josje, Shoemark, Amelia, Shteinberg, Michal, Boersma, Wim, Elborn, J. Stuart, Aliberti, Stefano, Ringshausen, Felix C., Chalmers, James D., Goeminne, Pieter C., Polverino, Eva, Dimakou, Katerina, Traversi, Letizia, Bossios, Apostolos, Haworth, Charles S., Loebinger, Michael R., De Soyza, Anthony, Vendrell, Montserrat, Burgel, Pierre Régis, Mertsch, Pontus, McDonnell, Melissa, Škrgat, Sabina, Maiz Carro, Luis, Sibila, Oriol, van der Eerden, Menno, Kauppi, Paula, Hill, Adam T., Wilson, Robert, Milenkovic, Branislava, Menendez, Rosario, Murris, Marlene, Digalaki, Tonia, Crichton, Megan L., Borecki, Sermin, Obradovic, Dusanka, Nowinski, Adam, Amorim, Adelina, Torres, Antoni, Lorent, Natalie, Welte, Tobias, Blasi, Francesco, Van Braeckel, Eva, Altenburg, Josje, Shoemark, Amelia, Shteinberg, Michal, Boersma, Wim, Elborn, J. Stuart, Aliberti, Stefano, Ringshausen, Felix C., Chalmers, James D., and Goeminne, Pieter C.

Abstract

Background: Asthma is commonly reported in patients with a diagnosis of bronchiectasis. Objective: The aim of this study was to evaluate whether patients with bronchiectasis and asthma (BE+A) had a different clinical phenotype and different outcomes compared with patients with bronchiectasis without concomitant asthma. Methods: A prospective observational pan-European registry (European Multicentre Bronchiectasis Audit and Research Collaboration) enrolled patients across 28 countries. Adult patients with computed tomography–confirmed bronchiectasis were reviewed at baseline and annual follow-up visits using an electronic case report form. Asthma was diagnosed by the local investigator. Follow-up data were used to explore differences in exacerbation frequency between groups using a negative binomial regression model. Survival analysis used Cox proportional hazards regression. Results: Of 16,963 patients with bronchiectasis included for analysis, 5,267 (31.0%) had investigator-reported asthma. Patients with BE+A were younger, were more likely to be female and never smokers, and had a higher body mass index than patients with bronchiectasis without asthma. BE+A was associated with a higher prevalence of rhinosinusitis and nasal polyps as well as eosinophilia and Aspergillus sensitization. BE+A had similar microbiology but significantly lower severity of disease using the bronchiectasis severity index. Patients with BE+A were at increased risk of exacerbation after adjustment for disease severity and multiple confounders. Inhaled corticosteroid (ICS) use was associated with reduced mortality in patients with BE+A (adjusted hazard ratio 0.78, 95% CI 0.63-0.95) and reduced risk of hospitalization (rate ratio 0.67, 95% CI 0.67-0.86) compared with control subjects without asthma and not receiving ICSs. Conclusions: BE+A was common and was associated with an increased risk of exacerbations and improved outcomes with ICS use. Unexpectedly we identified significantly lower

Published
2024

24. Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)

Author

Aliberti, Stefano, Ringshausen, Felix C., Dhar, Raja, Haworth, Charles S., Loebinger, Michael R., Dimakou, Katerina, Crichton, Megan L., De Soyza, Anthony, Vendrell, Montse, Burgel, Pierre-Regis, McDonnell, Melissa, Skrgat, Sabina, Maiz Carro, Luis, de Roux, Andres, Sibila, Oriol, Bossios, Apostolos, van der Eerden, Menno, Kauppi, Paula, Wilson, Robert, Milenkovic, Branislava, Menendez, Rosario, Murris, Marlene, Borekci, Sermin, Munteanu, Oxana, Obradovic, Dusanka, Nowinski, Adam, Amorim, Adelina, Torres, Antoni, Lorent, Natalie, Van Braeckel, Eva, Altenburg, Josje, Shoemark, Amelia, Shteinberg, Michal, Boersma, Wim, Goeminne, Pieter C., Elborn, J. Stuart, Hill, Adam T., Welte, Tobias, Blasi, Francesco, Polverino, Eva, Chalmers, James D., Aliberti, Stefano, Ringshausen, Felix C., Dhar, Raja, Haworth, Charles S., Loebinger, Michael R., Dimakou, Katerina, Crichton, Megan L., De Soyza, Anthony, Vendrell, Montse, Burgel, Pierre-Regis, McDonnell, Melissa, Skrgat, Sabina, Maiz Carro, Luis, de Roux, Andres, Sibila, Oriol, Bossios, Apostolos, van der Eerden, Menno, Kauppi, Paula, Wilson, Robert, Milenkovic, Branislava, Menendez, Rosario, Murris, Marlene, Borekci, Sermin, Munteanu, Oxana, Obradovic, Dusanka, Nowinski, Adam, Amorim, Adelina, Torres, Antoni, Lorent, Natalie, Van Braeckel, Eva, Altenburg, Josje, Shoemark, Amelia, Shteinberg, Michal, Boersma, Wim, Goeminne, Pieter C., Elborn, J. Stuart, Hill, Adam T., Welte, Tobias, Blasi, Francesco, Polverino, Eva, and Chalmers, James D.

Abstract

Background A validated 4-point sputum colour chart can be used to objectively evaluate the levels of airway inflammation in bronchiectasis patients. In the European Bronchiectasis Registry (EMBARC), we tested whether sputum colour would be associated with disease severity and clinical outcomes. Methods We used a prospective, observational registry of adults with bronchiectasis conducted in 31 countries. Patients who did not produce spontaneous sputum were excluded from the analysis. The Murray sputum colour chart was used at baseline and at follow-up visits. Key outcomes were frequency of exacerbations, hospitalisations for severe exacerbations and mortality during up to 5-year follow-up. Results 13 484 patients were included in the analysis. More purulent sputum was associated with lower forced expiratory volume in 1 s (FEV 1), worse quality of life, greater bacterial infection and a higher bronchiectasis severity index. Sputum colour was strongly associated with the risk of future exacerbations during follow-up. Compared to patients with mucoid sputum (reference group), patients with mucopurulent sputum experienced significantly more exacerbations (incident rate ratio (IRR) 1.29, 95% CI 1.22–1.38; p<0.0001), while the rates were even higher for patients with purulent (IRR 1.55, 95% CI 1.44–1.67; p<0.0001) and severely purulent sputum (IRR 1.91, 95% CI 1.52–2.39; p<0.0001). Hospitalisations for severe exacerbations were also associated with increasing sputum colour with rate ratios, compared to patients with mucoid sputum, of 1.41 (95% CI 1.29–1.56; p<0.0001), 1.98 (95% CI 1.77–2.21; p<0.0001) and 3.05 (95% CI 2.25–4.14; p<0.0001) for mucopurulent, purulent and severely purulent sputum, respectively. Mortality was significantly increased with increasing sputum purulence, hazard ratio 1.12 (95% CI 1.01–1.24; p=0.027), for each increment in sputum purulence. Conclusion Sputum colour is a simple marker of disease severity and future ris

Published
2024

30. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry

Author

Dhar, Raja, Singh, Sheetu, Talwar, Deepak, Mohan, Murali, Tripathi, Surya Kant, Swarnakar, Rajesh, Trivedi, Sonali, Rajagopala, Srinivas, D'Souza, George, Padmanabhan, Arjun, Baburao, Archana, Mahesh, Padukudru Anand, Ghewade, Babaji, Nair, Girija, Jindal, Aditya, Jayadevappa, Gayathri Devi H, Sawhney, Honney, Sarmah, Kripesh Ranjan, Saha, Kaushik, Anantharaj, Suresh, Khanna, Arjun, Gami, Samir, Shah, Arti, Shah, Arpan, Dutt, Naveen, Garg, Himanshu, Vyas, Sunil, Venugopal, Kummannoor, Prasad, Rajendra, Aleemuddin, Naveed M, Karmakar, Saurabh, Singh, Virendra, Jindal, Surinder Kumar, Sharma, Shubham, Prajapat, Deepak, Chandrashekaria, Sagar, McDonnell, Melissa J, Mishra, Aditi, Rutherford, Robert, Ramanathan, Ramanathan Palaniappan, Goeminne, Pieter C, Vasudev, Preethi, Dimakou, Katerina, Crichton, Megan L, Jayaraj, Biiligere Siddaiah, Kungwani, Rahul, Das, Akanksha, Sawhney, Mehneet, Polverino, Eva, Torres, Antoni, Gulecha, Nayan Sri, Shteinberg, Michal, De Soyza, Anthony, Mangala, Anshul, Shah, Palak, Chauhan, Nishant Kumar, Jajodia, Nikita, Singhal, Ashutosh, Batra, Sakshi, Hasan, Ashfaq, Limaye, Sneha, Salvi, Sundeep, Aliberti, Stefano, and Chalmers, James D

Published
2019
Full Text
View/download PDF

31. Structural Lung Disease and Clinical Phenotype in Bronchiectasis Patients: The EMBARC CT Study.

Author

Pieters, Angelina L. P., van der Veer, Tjeerd, Meerburg, Jennifer J., Andrinopoulou, Eleni-Rosalina, van der Eerden, Menno M., Ciet, Pierluigi, Aliberti, Stefano, Burgel, Pierre-Regis, Crichton, Megan L., Shoemark, Amelia, Goeminne, Pieter C., Shteinberg, Michal, Loebinger, Michael R., Haworth, Charles S., Blasi, Francesco, Tiddens, Harm A. W. M., Caudri, Daan, and Chalmers, James D.

Subjects
CILIARY motility disorders, LUNG diseases, ATELECTASIS, BRONCHIECTASIS, DYSKINESIAS, CHRONIC obstructive pulmonary disease, MYCOBACTERIAL diseases
Abstract

Rationale: Chest computed tomography (CT) scans are essential to diagnose and monitor bronchiectasis (BE). To date, few quantitative data are available about the nature and extent of structural lung abnormalities (SLAs) on CT scans of patients with BE. Objectives: To investigate SLAs on CT scans of patients with BE and the relationship of SLAs to clinical features using the EMBARC (European Multicenter Bronchiectasis Audit and Research Collaboration) registry. Methods: CT scans from patients with BE included in the EMBARC registry were analyzed using the validated Bronchiectasis Scoring Technique for CT (BEST-CT). The subscores of this instrument are expressed as percentages of total lung volume. The items scored are atelectasis/consolidation, BE with and without mucus plugging (MP), airway wall thickening, MP, ground-glass opacities, bullae, airways, and parenchyma. Four composite scores were calculated: total BE (i.e., BE with and without MP), total MP (i.e., BE with MP plus MP alone), total inflammatory changes (i.e., atelectasis/consolidation plus total MP plus ground-glass opacities), and total disease (i.e., all items but airways and parenchyma). Measurements and Main Results: CT scans of 524 patients with BE were analyzed. Mean subscores were 4.6 (range, 2.3–7.7) for total BE, 4.2 (1.2–8.1) for total MP, 8.3 (3.5–16.7) for total inflammatory changes, and 14.9 (9.1–25.9) for total disease. BE associated with primary ciliary dyskinesia was associated with more SLAs, whereas chronic obstructive pulmonary disease was associated with fewer SLAs. Lower FEV1, longer disease duration, Pseudomonas aeruginosa and nontuberculous mycobacterial infections, and severe exacerbations were all independently associated with worse SLAs. Conclusions: The type and extent of SLAs in patients with BE are highly heterogeneous. Strong relationships between radiological disease and clinical features suggest that CT analysis may be a useful tool for clinical phenotyping. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. The Association between Bronchiectasis and Chronic Obstructive Pulmonary Disease: Data from the European Bronchiectasis Registry (EMBARC).

Author

Polverino, Eva, De Soyza, Anthony, Dimakou, Katerina, Traversi, Letizia, Bossios, Apostolos, Crichton, Megan L., Ringshausen, Felix C., Vendrell, Montserrat, Burgel, Pierre-Régis, Haworth, Charles S., Loebinger, Michael R., Lorent, Natalie, Pink, Isabell, McDonnell, Melissa, Skrgat, Sabina, Carro, Luis M., Sibila, Oriol, van der Eerden, Menno, Kauppi, Paula, and Shoemark, Amelia

Subjects
BRONCHIECTASIS, CHRONIC obstructive pulmonary disease
Abstract

Rationale: COPD and bronchiectasis are commonly reported together. Studies report varying impacts of co-diagnosis on outcomes, which may be related to different definitions of disease used across studies. Objectives: To investigate the prevalence of chronic obstructive pulmonary disease (COPD) associated with bronchiectasis and its relationship with clinical outcomes. We further investigated the impact of implementing the standardized ROSE criteria (radiological bronchiectasis [R], obstruction [FEV1/FVC ratio <0.7; O], symptoms [S], and exposure [⩾10 pack-years of smoking; E]), an objective definition of the association of bronchiectasis with COPD. Methods: Analysis of the EMBARC (European Bronchiectasis Registry), a prospective observational study of patients with computed tomography–confirmed bronchiectasis from 28 countries. The ROSE criteria were used to objectively define the association of bronchiectasis with COPD. Key outcomes during a maximum of 5 years of follow-up were exacerbations, hospitalization, and mortality. Measurements and Main Results: A total of 16,730 patients with bronchiectasis were included; 4,336 had a clinician-assigned codiagnosis of COPD, and these patients had more exacerbations, worse quality of life, and higher severity scores. We observed marked overdiagnosis of COPD: 22.2% of patients with a diagnosis of COPD did not have airflow obstruction and 31.9% did not have a history of ⩾10 pack-years of smoking. Therefore, 2,157 patients (55.4%) met the ROSE criteria for COPD. Compared with patients without COPD, patients who met the ROSE criteria had increased risks of exacerbations and exacerbations resulting in hospitalization during follow-up (incidence rate ratio, 1.25; 95% confidence interval, 1.15–1.35; vs. incidence rate ratio, 1.69; 95% confidence interval, 1.51–1.90, respectively). Conclusions: The label of COPD is often applied to patients with bronchiectasis who do not have objective evidence of airflow obstruction or a smoking history. Patients with a clinical label of COPD have worse clinical outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Neutrophil-Mediated Killing of Pseudomonas aeruginosa in Patients with Bronchiectasis.

Author

Long, Merete B., Gilmour, Amy, Kehl, Margaret, Tabor, David E., Keller, Ashley E., Warrener, Paul, Gopalakrishnan, Vancheswaran, Rosengren, Sanna, Crichton, Megan L., McIntosh, Eve, Giam, Yan Hui, Keir, Holly R., Brailsford, Wayne, Hughes, Rod, Belvisi, Maria G., Sellman, Bret R., DiGiandomenico, Antonio, and Chalmers, James D.

Subjects
BISPECIFIC antibodies, BRONCHIECTASIS, PSEUDOMONAS aeruginosa, WHOLE genome sequencing, ANTIBODY titer
Abstract

Rationale:Pseudomonas aeruginosa infection is associated with worse outcomes in bronchiectasis. Impaired neutrophil antimicrobial responses contribute to bacterial persistence. Gremubamab is a bivalent, bispecific monoclonal antibody targeting Psl exopolysaccharide and the type 3 secretion system component PcrV. Objectives: This study evaluated the efficacy of gremubamab to enhance killing of P. aeruginosa by neutrophils from patients with bronchiectasis and to prevent P. aeruginosa–associated cytotoxicity. Methods:P. aeruginosa isolates from a global bronchiectasis cohort (n = 100) underwent whole-genome sequencing to determine target prevalence. Functional activity of gremubamab against selected isolates was tested in vitro and in vivo. Patients with bronchiectasis (n = 11) and control subjects (n = 10) were enrolled, and the effect of gremubamab in peripheral blood neutrophil opsonophagocytic killing (OPK) assays against P. aeruginosa was evaluated. Serum antibody titers to Psl and PcrV were determined (n = 30; 19 chronic P. aeruginosa infection, 11 no known P. aeruginosa infection), as was the effect of gremubamab treatment in OPK and anti–cytotoxic activity assays. Measurements and Main Results: Psl and PcrV were conserved in isolates from chronically infected patients with bronchiectasis. Seventy-three of 100 isolates had a full psl locus, and 99 of 100 contained the pcrV gene, with 20 distinct full-length PcrV protein subtypes identified. PcrV subtypes were successfully bound by gremubamab and the monoclonal antibody–mediated potent protective activity against tested isolates. Gremubamab increased bronchiectasis patient neutrophil-mediated OPK (+34.6 ± 8.1%) and phagocytosis (+70.0 ± 48.8%), similar to effects observed in neutrophils from control subjects (OPK, +30.1 ± 7.6%). No evidence of competition between gremubamab and endogenous antibodies was found, with protection against P. aeruginosa–induced cytotoxicity and enhanced OPK demonstrated with and without addition of patient serum. Conclusions: Gremubamab enhanced bronchiectasis patient neutrophil phagocytosis and killing of P. aeruginosa and reduced virulence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease

Author

Dicker, Alison J., Crichton, Megan L., Pumphrey, Eleanor G., Cassidy, Andrew J., Suarez-Cuartin, Guillermo, Sibila, Oriol, Furrie, Elizabeth, Fong, Christopher J., Ibrahim, Wasyla, Brady, Gill, Einarsson, Gisli G., Elborn, J. Stuart, Schembri, Stuart, Marshall, Sara E., Palmer, Colin N.A., and Chalmers, James D.

Published
2018
Full Text
View/download PDF

37. The bronchiectasis exacerbation definition in a real-world setting: data from the EMBARC registry

Author

Nigro, Mattia, primary, Crichton, Megan, additional, Goeminne, Pieter C., additional, Lorent, Natalie, additional, Dimakou, Katerina, additional, Sibila, Oriol, additional, Menendez, Rosario, additional, Shteinberg, Michal, additional, Blasi, Francesco, additional, Welte, Tobias, additional, Polverino, Eva, additional, Chalmers, James D., additional, and Aliberti, Stefano, additional

Published
2023
Full Text
View/download PDF

38. The microbiology of bronchiectasis in Europe: Data from the European Bronchiectasis Registry (EMBARC)

Author

Chalmers, James D., primary, Polverino, Eva, additional, Crichton, Megan, additional, Ringshausen, Felix, additional, De Soyza, Anthony, additional, Vendrell, Montserrat, additional, Regis Burgel, Pierre, additional, Haworth, Charles, additional, Loebinger, Michael, additional, Dimakou, Katerina, additional, Murris, Marlene, additional, Wilson, Robert, additional, Hill, Adam, additional, Menendez, Rosario, additional, Torres, Antoni, additional, Welte, Tobias, additional, Blasi, Francesco, additional, Altenburg, Josje, additional, Shteinberg, Michal, additional, Boersma, Wim, additional, Elborn, Stuart, additional, Goeminne, Pieter, additional, and Aliberti, Stefano, additional

Published
2023
Full Text
View/download PDF

39. Proteinase 3 as a marker of clinical severity in bronchiectasis: Data from the EMBARC-BRIDGE study

Author

Johnson, Emma, primary, Crichton, Megan L, additional, Keir, Holly R, additional, Long, Merete, additional, Shuttleworth, Morven, additional, Cant, Erin, additional, De Soyza, Anthony, additional, Dimakou, Katerina, additional, Shteinberg, Michal, additional, Spinou, Arietta, additional, Ringshausen, Felix, additional, Lorent, Natalie, additional, Goeminne, Pieter, additional, Loebinger, Michael, additional, Chotirmall, Sanjay, additional, Dhar, Raja, additional, Haworth, Charles, additional, Altenburg, Josje, additional, Blasi, Francesco, additional, Welte, Tobias, additional, Siblia, Oriol, additional, Aliberti, Stefano, additional, Shoemark, Amelia, additional, and Chalmers, James D, additional

Published
2023
Full Text
View/download PDF

40. Risk of SARS-CoV-2 infection and disease severity among people with bronchiectasis: analysis of three population registries

Author

Shteinberg, Michal, primary, Sibila, Oriol, additional, Stein, Nili, additional, Faner, Rosa, additional, Jordan, Alexander, additional, Olvera, Nuria, additional, Sivapalan, Pradeesh, additional, Jensen, Jens Ulrik, additional, Crichton, Megan, additional, Chalmers, James, additional, Meyer, Christian, additional, and Saliba, Walid, additional

Published
2023
Full Text
View/download PDF

41. The airway microbiome in Bronchiectasis-COPD overlap: data from the EMBARC-BRIDGE study

Author

Keir, Holly R., primary, Dicker, Alison J., additional, Richardson, Hollian, additional, Kewin, Ellie, additional, Perea Soriano, Lidia, additional, Pollock, Jennifer, additional, Giam, Yan H, additional, Crichton, Megan, additional, Choi, Hayoung, additional, Cant, Erin, additional, Finch, Simon, additional, Fong, Christopher J., additional, Blasi, Francesco, additional, Shoemark, Amelia, additional, Sibila, Oriol, additional, Aliberti, Stefano, additional, and Chalmers, James D, additional

Published
2023
Full Text
View/download PDF

42. Microbiology in inhaled antibiotic users with bronchiectasis: Data from the European Bronchiectasis Registry (EMBARC)

Author

Haworth, Charles, primary, Polverino, Eva, additional, Crichton, Megan, additional, Ringshausen, Felix, additional, De Soyza, Anthony, additional, Vendrell, Montserrat, additional, Regis-Burgel, Pierre, additional, Loebinger, Michael, additional, Dimakou, Katerina, additional, Menendez, Rosario, additional, Torres, Antoni, additional, Welte, Tobas, additional, Blasi, Francesco, additional, Shteinberg, Michal, additional, Boersma, Wim, additional, Elborn, Stuart, additional, Goeminne, Pieter, additional, Aliberti, Stefano, additional, and Chalmers, James, additional

Published
2023
Full Text
View/download PDF

43. Sputum colour assessment and clinical outcomes in bronchiectasis: data from the EMBARC Registry

Author

Crichton, Megan, primary, Polverino, Eva, additional, Ringshausen, Felix, additional, De Soyza, Anthony, additional, Vendrell, Montserrat, additional, Regis Burgel, Pierre, additional, Haworth, Charles, additional, Loebinger, Michael, additional, Dinamku, Katerina, additional, Murris, Marlene, additional, Wilson, Robert, additional, Hill, Adam, additional, Menendes, Rosario, additional, Torres, Antoni, additional, Welte, Tobias, additional, Blasi, Francesco, additional, Altenburg, Josje, additional, Shteinberg, Michal, additional, Boersma, Wim, additional, Elborn, Stuart, additional, Goeminne, Pieter, additional, Aliberti, Stefano, additional, and Chalmers, James, additional

Published
2023
Full Text
View/download PDF

44. Pseudomonas aeruginosa eradication in patients with bronchiectasis: data from the EMBARC registry

Author

Nigro, Mattia, primary, Haworth, Charles, additional, Polverino, Eva, additional, Crichton, Megan L., additional, Ringsahusen, Felix C., additional, De Soyza, Anthony, additional, Vendrell, Montserrat, additional, Regis-Burgel, Pierre, additional, Loebinger, Michael R., additional, Dimakou, Katerina, additional, Menendez, Rosario, additional, Torres, Antoni, additional, Welte, Tobias, additional, Blasi, Francesco, additional, Shteinberg, Michal, additional, Boersma, Wim, additional, Elborn, J. Stuart, additional, Goeminne, Pieter C., additional, Chalmers, James D., additional, and Aliberti, Stefano, additional

Published
2023
Full Text
View/download PDF

45. The effect of different inhaled corticosteroids on airway bacterial load and the microbiome in COPD: a randomized controlled trial

Author

Richardson, Hollian, primary, Keir, Holly R, additional, Clarke, Clare, additional, Alferes De Lima, Daniela, additional, Veluchamy, Abirami, additional, Rauchhaus, Petra, additional, Pembridge, Thomas, additional, Crichton, Megan, additional, Pollock, Jennifer, additional, Finch, Simon, additional, Dicker, Alison J, additional, Billingham, Pauline, additional, Hussain, Furrah, additional, Band, Margaret, additional, Smith, Andrew, additional, Patel, Manish, additional, Paracha, Mohammad, additional, Choudhury, Gourab, additional, Dhasmana, Devesh, additional, Chaudhuri, Rekha, additional, Short, Philip M, additional, and Chalmers, James D, additional

Published
2023
Full Text
View/download PDF

46. Alpha-1 antitrypsin deficiency genotypes in a large international cohort study of bronchiectasis (EMBARC BRIDGE)

Author

Ringshausen, Felix C., primary, Lorent, Natalie, additional, De Soyza, Anthony, additional, Sibila, Oriol, additional, Polverino, Eva, additional, Altenburg, Josje, additional, Crichton, Megan L., additional, Shteinberg, Michal, additional, Goeminne, Pieter C., additional, Blasi, Francesco, additional, Welte, Tobias, additional, Aliberti, Stefano, additional, Shoemark, Amelia, additional, and Chalmers, James D., additional

Published
2023
Full Text
View/download PDF

47. Convergent validity of the Bronchiectasis Impact Measure: data from the EMBARC-BRIDGE study

Author

Crichton, Megan, primary, Spinou, Arietta, additional, Shoemark, Amelia, additional, Aliberti, Stefano, additional, Altenburg, Josje, additional, Blasi, Francesco, additional, Clarke, Clare, additional, Chotirmall, Sanjay, additional, Dhar, Raja, additional, Goeminne, Pieter, additional, Haworth, Chalres, additional, Loebinger, Michael, additional, Lorent, Natalie, additional, Polverino, Eva, additional, Ringshausen, Felix, additional, Shteinberg, Michal, additional, Sibila, Oriol, additional, Welte, Tobias, additional, and Chalmers, James, additional

Published
2023
Full Text
View/download PDF

48. Neutrophil metabolomics in bronchiectasis: data from the EMBARC BRIDGE study

Author

Shoemark, Amelia, primary, Giam, Yan Hui, additional, Gilmour, Amy, additional, Long, Merete B, additional, Keir, Holly R, additional, Pembridge, Thomas, additional, Hughes, Chloe, additional, Hull, Rebecca C, additional, Mcintosh, Eve, additional, Lind, Holly, additional, Crichton, Megan L, additional, Polverino, Eva, additional, Aliberti, Stefano, additional, Blasi, Francesco, additional, Goeminne, Pieter C, additional, Welte, Tobias, additional, Altenburg, Josje, additional, Shteinberg, Michal, additional, and Chalmers, James D, additional

Published
2023
Full Text
View/download PDF

49. Blood eosinophils, inhaled corticosteroids and exacerbations in bronchiectasis: Data from the EMBARC registry

Author

Pollock, Jennifer, primary, Polverino, Eva, additional, Crichton, Megan L., additional, Regis-Burgel, Pierre, additional, Haworth, Charles, additional, Dimakou, Katerina, additional, Loebinger, Michael R., additional, Menendez, Rosario, additional, Torres, Antoni, additional, Welte, Tobias, additional, Blasi, Francesco, additional, Ringshausen, Felix, additional, De Soyza, Anthony, additional, Vendrell, Montserrat, additional, Elborn, Stuart J., additional, Shoemark, Amelia, additional, Aliberti, Stefano, additional, Goeminne, Pieter, additional, and Chalmers, James D., additional

Published
2023
Full Text
View/download PDF

50. Risk of SARS-CoV-2 Infection and Disease Severity Among People With Bronchiectasis

Author

Shteinberg, Michal, primary, Sibila, Oriol, additional, Stein, Nili, additional, Faner, Rosa, additional, Jordan, Alexander, additional, Olvera, Nuria, additional, Sivapalan, Pradeesh, additional, Jensen, Jens Ulrik S., additional, Crichton, Megan, additional, Marrades, Pau, additional, Chalmers, James D., additional, Meyer, Christian N., additional, and Saliba, Walid, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results